Product Description
Travoprost ophthalmic is used to treat glaucoma (a condition in which increased pressure in the eye can lead to gradual loss of vision) and ocular hypertension (a condition which causes increased pressure in the eye). Travoprost is in a class of medications called prostaglandin analogs. It lowers pressure in the eye by increasing the flow of natural eye fluids out of the eye (Sourced from: https://medlineplus.gov/druginfo/meds/a602027.html)
Mechanisms of Action: PGF Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Ocular,Ophthalmic
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Hypertension | Glaucoma
Known Adverse Events: Hyperemia
Company: Alcon
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Armenia, Philippines, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Cataract|Glaucoma, Open-Angle|Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GLK-101-01 | P3 |
Recruiting |
Glaucoma, Open-Angle |
2025-02-01 |
95% |
| GLK-311-01 | P2 |
Recruiting |
Hypertension|Glaucoma, Open-Angle |
2024-08-01 |
32% |
| GLK-101-02 | P3 |
Active, not recruiting |
Cataract|Glaucoma, Open-Angle|Hypertension |
2024-03-18 |
38% |
| OTX-TIC-2020-201 | P2 |
Active, not recruiting |
Hypertension|Glaucoma, Open-Angle |
2024-01-01 |
32% |